A number of firms have modified their ratings and price targets on shares of Fate Therapeutics (NASDAQ: FATE) recently:
- 8/14/2026 – Fate Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $8.00 price target on the stock, up from $6.00.
- 8/14/2026 – Fate Therapeutics had its price target raised by Wells Fargo & Company from $2.50 to $3.50. They now have an “equal weight” rating on the stock.
- 8/14/2026 – Fate Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.
- 8/7/2026 – Fate Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.
Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.
See Also
- Five stocks we like better than Fate Therapeutics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Fate Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
